No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
www.bonesupport.comNo one on the platform currently holds BONEX.ST.
No tracked institution reports a position in BONEX.ST as of their last filing.
No one on the platform has traded BONEX.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 39.3% | — | — | — | ||
| Rev. Growth % | 30.7% | 45.4% | ||||
| Profit Margin % | 12.1% | 1.5% | -54.0% | |||
| Free Cash Flow Margin % | 18.4% | -6.9% | -54.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +26.9% | $4.98 | $4.66–$5.41 | — | 6 |
| 2027 | $2.0B | +32.2% | $7.48 | $6.60–$8.17 | — | 6 |
| 2028 | $2.5B | +26.1% | $10.20 | $9.48–$11.94 | — | 5 |
| 2029 | $2.9B | +15.8% | $12.38 | $11.67–$13.14 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-16 | $1.12 | $1.22 | +8.9% |
| 2026-04-22 | $0.96 | $0.81 | -16.6% |
| 2026-02-24 | $0.88 | $0.67 | -24.0% |
| 2025-10-23 | $0.85 | $0.52 | -39.2% |
| 2025-07-15 | $0.95 | $0.80 | -16.3% |
| +0.00% |
| $17.7B |
| — |
| BIOG-B.STBioGaia AB (publ) | $107.30 | +0.00% | $10.6B | — |
| EKTA-B.STElekta AB (publ) | $52.25 | +4.40% | $19.2B | — |
Source: Financial Modeling Prep · peers by sector/industry